help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazennec, G.
Right arrow Articles by Katzenellenbogen, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazennec, G.
Right arrow Articles by Katzenellenbogen, B. S.
Molecular Endocrinology 13 (6): 969-980
Copyright © 1999 by The Endocrine Society

Adenovirus-Mediated Delivery of a Dominant Negative Estrogen Receptor Gene Abrogates Estrogen-Stimulated Gene Expression and Breast Cancer Cell Proliferation

Gwendal Lazennec1, Joseph L. Alcorn and Benita S. Katzenellenbogen

Department of Molecular and Integrative Physiology (G.L., B.S.K.) and Department of Cell and Structural Biology (B.S.K.) University of Illinois Urbana, Illinois 61801
Department of Biochemistry (J.L.A.) University of Texas Southwestern Medical School Dallas, Texas 75235

Dominant negative estrogen receptors are transcriptionally inactive, altered forms of the estrogen receptor (ER) that can dimerize with the ER and have the potential to inactivate the biological functions of this receptor. Here, we provide the first report that adenoviral delivery of a dominant negative ER to ER-positive breast cancer cells is able to effectively suppress estrogen-stimulated cell proliferation and the hormonal induction of endogenous genes. We constructed recombinant adenoviral vectors expressing a dominant negative ER (S554 fs, Ad-fs) or, for comparison, antisense ER (Ad-AS), or the sense wild-type ER (Ad-WT). Expression of the dominant negative ER or antisense ER, but not wild-type ER, blocked estradiol stimulation of the estrogen-responsive genes pS2 and c-myc. The dominant negative ER also fully abolished the estradiol-induced increase in proliferation of MCF-7 breast cancer cells, as did the antisense ER. The antiproliferative effects of the dominant negative and antisense ERs are explained by an increase in the number of cells in the G0/G1 stage of the cell cycle and decrease in the number of cells in G2/M as determined by flow cytometry, and also by a significant increase in the percentage of cells undergoing apoptosis. Our data strongly support the idea that targeting ER action using recombinant viral delivery of dominant negative ERs is an effective way to suppress ER-positive breast cancer cell proliferation and suggests the potential attractiveness of dominant negative gene therapy approaches targeted to the ER for the treatment of hormone-responsive breast cancer.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
E. C. Chang, T. H. Charn, S.-H. Park, W. G. Helferich, B. Komm, J. A. Katzenellenbogen, and B. S. Katzenellenbogen
Estrogen Receptors {alpha} and {beta} as Determinants of Gene Expression: Influence of Ligand, Dose, and Chromatin Binding
Mol. Endocrinol., May 1, 2008; 22(5): 1032 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. H. Hassan, S. A. Salama, H. M. M. Arafa, F. M. A. Hamada, and A. Al-Hendy
Adenovirus-Mediated Delivery of a Dominant-Negative Estrogen Receptor Gene in Uterine Leiomyoma Cells Abrogates Estrogen- and Progesterone-Regulated Gene Expression
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3949 - 3957.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. C. Chang, J. Frasor, B. Komm, and B. S. Katzenellenbogen
Impact of Estrogen Receptor {beta} on Gene Networks Regulated by Estrogen Receptor {alpha} in Breast Cancer Cells
Endocrinology, October 1, 2006; 147(10): 4831 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Frasor, E. C. Chang, B. Komm, C.-Y. Lin, V. B. Vega, E. T. Liu, L. D. Miller, J. Smeds, J. Bergh, and B. S. Katzenellenbogen
Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.
Cancer Res., July 15, 2006; 66(14): 7334 - 7340.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Z. T. Ruiz-Cortes, S. Kimmins, L. Monaco, K. H. Burns, P. Sassone-Corsi, and B. D. Murphy
Estrogen Mediates Phosphorylation of Histone H3 in Ovarian Follicle and Mammary Epithelial Tumor Cells via the Mitotic Kinase, Aurora B
Mol. Endocrinol., December 1, 2005; 19(12): 2991 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J. Huang, X. Li, C. A. Maguire, R. Hilf, R. A. Bambara, and M. Muyan
Binding of Estrogen Receptor {beta} to Estrogen Response Element in Situ Is Independent of Estradiol and Impaired by Its Amino Terminus
Mol. Endocrinol., November 1, 2005; 19(11): 2696 - 2712.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
E. J. Lee and J L. Jameson
Gene therapy of pituitary diseases
J. Endocrinol., June 1, 2005; 185(3): 353 - 362.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. Rai, A. Frolova, J. Frasor, A. E. Carpenter, and B. S. Katzenellenbogen
Distinctive Actions of Membrane-Targeted Versus Nuclear Localized Estrogen Receptors in Breast Cancer Cells
Mol. Endocrinol., June 1, 2005; 19(6): 1606 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Stossi, D. H. Barnett, J. Frasor, B. Komm, C. R. Lyttle, and B. S. Katzenellenbogen
Transcriptional Profiling of Estrogen-Regulated Gene Expression via Estrogen Receptor (ER) {alpha} or ER{beta} in Human Osteosarcoma Cells: Distinct and Common Target Genes for These Receptors
Endocrinology, July 1, 2004; 145(7): 3473 - 3486.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
T. Watanabe, M. Akishita, T. Nakaoka, K. Kozaki, Y. Miyahara, H. He, Y. Ohike, T. Ogita, S. Inoue, M. Muramatsu, et al.
Estrogen receptor {beta} mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation
Cardiovasc Res, September 1, 2003; 59(3): 734 - 744.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Garcia Pedrero, P. Zuazua, C. Martinez-Campa, P. S. Lazo, and S. Ramos
The Naturally Occurring Variant of Estrogen Receptor (ER) ER{Delta}E7 Suppresses Estrogen-Dependent Transcriptional Activation by Both Wild-Type ER{alpha} and ER{beta}
Endocrinology, July 1, 2003; 144(7): 2967 - 2976.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Pedram, M. Razandi, M. Aitkenhead, C. C. W. Hughes, and E. R. Levin
Integration of the Non-genomic and Genomic Actions of Estrogen. MEMBRANE-INITIATED SIGNALING BY STEROID TO TRANSCRIPTION AND CELL BIOLOGY
J. Biol. Chem., December 20, 2002; 277(52): 50768 - 50775.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-C. Hu, C.-R. Shyr, W. Che, X.-M. Mu, E. Kim, and C. Chang
Suppression of Estrogen Receptor-mediated Transcription and Cell Growth by Interaction with TR2 Orphan Receptor
J. Biol. Chem., September 6, 2002; 277(37): 33571 - 33579.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-R. Shyr, Y.-C. Hu, E. Kim, and C. Chang
Modulation of Estrogen Receptor-mediated Transactivation by Orphan Receptor TR4 in MCF-7 Cells
J. Biol. Chem., April 19, 2002; 277(17): 14622 - 14628.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. J. Lee, W. R. Duan, M. Jakacka, B. D. Gehm, and J. L. Jameson
Dominant Negative ER Induces Apoptosis in GH4 Pituitary Lactotrope Cells and Inhibits Tumor Growth in Nude Mice
Endocrinology, September 1, 2001; 142(9): 3756 - 3763.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Lazennec, D. Bresson, A. Lucas, C. Chauveau, and F. Vignon
ER{beta} Inhibits Proliferation and Invasion of Breast Cancer Cells
Endocrinology, September 1, 2001; 142(9): 4120 - 4130.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Oesterreich, P. Zhang, R. L. Guler, X. Sun, E. M. Curran, W. V. Welshons, C. K. Osborne, and A. V. Lee
Re-expression of Estrogen Receptor {alpha} in Estrogen Receptor {alpha}-negative MCF-7 Cells Restores both Estrogen and Insulin-like Growth Factor-mediated Signaling and Growth
Cancer Res., August 1, 2001; 61(15): 5771 - 5777.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. Lazennec, L. Canaple, D. Saugy, and W. Wahli
Activation of Peroxisome Proliferator-Activated Receptors (PPARs) by Their Ligands and Protein Kinase A Activators
Mol. Endocrinol., December 1, 2000; 14(12): 1962 - 1975.
[Abstract] [Full Text]

Home page
 Mol. Endocrinol.Home page
P.-Y. Chien, M. Ito, Y. Park, T. Tagami, B. D. Gehm, and J. L. Jameson
A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells
Mol. Endocrinol., December 1, 1999; 13(12): 2122 - 2136.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society